RxDoctor Payments Data

Tracy Smith, MD

Internal Medicine · Prescott, AZNPI 1821067448

Payments from drug & device makers

$308in general payments, 2019–2025

Across 18 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$72
  • Pfizer$70
  • Novartis$43
  • AbbVie$39
  • Novo Nordisk$36
  • Idorsia Pharmaceuticals US Inc$26
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$308100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen5$72
Pfizer4$70
Novartis2$43
AbbVie(2 entities)2$39
Novo Nordisk2$36
Idorsia Pharmaceuticals US Inc2$26
Astellas Pharma US Inc1$22

How this compares

$308 in reported general payments places this provider in the 60th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$52,298
Medicare patients
398
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$81,537
OzempicSemaglutide45$61,547
JanuviaSitagliptin Phosphate45$53,521
JardianceEmpagliflozin36$37,503
XareltoRivaroxaban28$36,116
MounjaroTirzepatide14$16,630
MyrbetriqMirabegron28$14,964
CreonLipase/Protease/Amylase11$8,958
Levothyroxine Sodium598$6,954
Atorvastatin Calcium724$6,585
SynthroidLevothyroxine Sodium118$5,609
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$5,419
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,933
Tamsulosin Hcl204$3,974
Rosuvastatin Calcium295$3,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$81,53767 claims
Novo NordiskOzempic, Novolog$36$64,17756 claims
Astellas Pharma US IncMyrbetriq$22$14,96428 claims
AbbVieCreon, Synthroid$39$14,568129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Prescott

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →